secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2025-02-06T23:59:59+00:00
Accession:  0001724521-25-000024
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Biosciences appoints Dietmar Berger to board replacing Merdad Parsey
--------------------------------------------------------------------------

- Merdad Parsey resigned from Arcus board effective upon Gilead's new director designee; he left Gilead.
- Dietmar Berger, Gilead's CMO since Jan 2025, appointed as Class II director to fill vacancy.
- Dr. Berger will not receive compensation for board service; Arcus will enter standard indemnification agreement.
- Changes made pursuant to Amended and Restated Investor Rights Agreement between Arcus and Gilead.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000172452125000024/0001724521-25-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000172452125000024/rcus-20250206.htm
  HTML page:      https://secwatch.observer/filing/0001724521-25-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer